Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19 patients

Phase 3

Recruiting

• Conditions: covid-19 disease.; covid-19 disease; U07.1

• Registration Number: IRCT20200510047383N1
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

COVID-19 disease confirmed by chest ct and PCR
No pregnancy
No breastfeeding
Negative PPD
No bacterial pneumonia (negative sputum and urine culture)
Not use of atorvastatin , alprazolam , amlodipine , MTX , hydroxychloroquine ,
Informed consent

Exclusion Criteria

Disapproval of covid-19 disease by chest computed tomography and PCR
Positive PPD
Bacterial pneumonia (negative sputum and urine culture)
Pregnancy
Breastfeeding
Use of atorvastatin , alprazolam , amlodipine , MTX , hydroxychloroquine by the patient
Lack of Informed consent

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Investigation of mortality rate of CIVID-19 patients. Timepoint: After treatment. Method of measurement: Situation of the patient's life.

Secondary Outcome Measures

Name	Time	Method
The average number of hospitalization days for COVID-19 patients. Timepoint: End of treatment. Method of measurement: Day.;Average platelets count. Timepoint: Before and after treatment. Method of measurement: Complete Blood Count (CBC) test.;Average percentage of oxygen saturation. Timepoint: Every 12 hours. Method of measurement: Puls oximeter.